Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAZITHROMYCIN (azithromycin) by Molecular Devices is 12. Approved for development of drug-resistant bacteria, maintain the effectiveness of azithromycin, other antibacterial drugs and 2 more indications. First approved in 2015.
Drug data last refreshed 19h ago
12.1 Mechanism of Action Azithromycin is a macrolide antibacterial drug. [see ] 12.2 Pharmacodynamics Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under the concentration-time curve to minimum inhibitory concentration…
Worked on AZITHROMYCIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Azithromycin Before Induction
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo